Brean Capital Downgrades Medivation (MDVN) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Stocks and yen struggle as tech troubles weigh
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steady as US demand concerns balance Middle East conflict risks
- Yen hits fresh 34-year lows against dollar ahead of BOJ meeting
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Citi Downgrades Medivation (MDVN) to Neutral
August 22, 2016 2:43 PM EDTCiti downgraded Medivation (NASDAQ: MDVN) from Buy to Neutral.
For an analyst ratings summary and ratings history on Medivation click here. For more ratings news on Medivation click here.
Shares of Medivation closed at $67.16 yesterday.
... MoreMoody's Affirms Ratings on Pfizer (PFE) Amid Move to Acquire Medivation (MDVN); Outlook Remains Negative
August 22, 2016 2:13 PM EDTMoody's Investors Service affirmed the ratings of Pfizer Inc. (NYSE: PFE) and related subsidiaries, including the A1 senior unsecured long-term rating and the Prime-1 commercial paper rating. The rating outlook remains negative. This action follows the announcement that Pfizer will acquire Medivation, Inc. (unrated) for approximately $14 billion.
"The affirmation reflects Pfizer's strong financial profile and the use of existing cash to fund the Medivation acquisition," stated Michael Levesque, Moody's Senior Vice President. Medivation brings a growing, profitable oncology product as well as several pipeline opportunities. Risk factors include high valuation, and the... More
Wedbush Downgrades Medivation (MDVN) to Neutral
August 22, 2016 1:00 PM EDTWedbush downgraded Medivation (NASDAQ: MDVN) from Outperform to Neutral.
For an analyst ratings summary and ratings history on Medivation click here. For more ratings news on Medivation click here.
Shares of Medivation closed at $67.16 yesterday.
... MoreBMO 'Neutral to Positive' on Pfizer's (PFE) Medivation Takeover
August 22, 2016 12:09 PM EDTBMO Capital analyst Alex Arfaei weighed in on Pfizer's (NYSE: PFE) $14 billion takeover of Medivation (NASDAQ: MDVN), saying he is Neutral to Positive on the deal despite the "arguably rich" multiple.
"... Xtandi and pipeline complement Pfizer's oncology portfolio well and... More
Barclays Downgrades Medivation (MDVN) to Equalweight
August 22, 2016 11:48 AM EDTBarclays downgraded Medivation (NASDAQ: MDVN) from Overweight to Equalweight.
For an analyst ratings summary and ratings history on Medivation click here. For more ratings news on Medivation click here.
Shares of Medivation closed at $67.16 yesterday.
... MorePfizer (PFE) to Acquire Medivation (MDVN) in $14B Deal
August 22, 2016 6:45 AM EDTPfizer Inc. (NYSE: PFE) and Medivation, Inc. (Nasdaq: MDVN) announced that they have entered into a definitive merger agreement under which Pfizer will acquire Medivation, a biopharmaceutical company focused on developing and commercializing small molecules for oncology, for $81.50 a share in cash for a total enterprise value of approximately $14 billion. The Boards of Directors of both companies have unanimously approved the merger, which is expected to be immediately accretive to Pfizers Adjusted Diluted EPS upon closing, approximately $0.05 accretive in the first full year after close with... More
